Entrada Therapeutics disclosed its fourth‑quarter and full‑year 2025 financial results on February 26, 2026. The company reported an earnings per share of $‑0.94, beating the consensus estimate of $‑1.32 by $0.38. Revenue was expected to be $1.29 million, but the fact‑check report does not provide the actual figure.
The earnings beat indicates that the company performed better than analysts had anticipated, although it remains unprofitable. The fact‑check report does not specify the drivers behind the improvement, so the article cannot attribute the beat to particular cost controls or revenue mix changes.
The company’s guidance for the remainder of 2025 was not disclosed in the fact‑check, so investors will need to await further updates to assess the outlook for the business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.